发布时间: 2025 - 09 - 11
On September 11, 2025, Beijing Huahaizhongtian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huahaizhongtian," stock code: 2563.HK) announced that the first patient has been dosed in an international multicenter Phase II/III clinical study (BG02-2502) evaluating Utidelone capsules (UTD2) for the treatment of patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This is the first international multicenter clinical study initiated globally for UTD2 in the treatment of advanced solid tumors, followi...
浏览次数:2
发布时间: 2025 - 09 - 08
On September 8, 2025, according to information from Hangzhou, Zhejiang, and the United States, Xinyuan Pharmaceutical announced very positive results from the global Phase IIb/III clinical trial of ABP-671 for the treatment of gout. This study was a multicenter, randomized, double-blind, allopurinol-positive (Treat-to-Target) and placebo-controlled global study conducted across multiple countries and regions, including the United States, Europe, Australia, Latin America, and Taiwan, with a 6-month primary endpoint evaluation period.The results showed that this clinical trial met all primary an...
浏览次数:1
发布时间: 2025 - 09 - 03
September 3, 2025 marks the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War. On this important day, which carries great triumph, glorious history, and an indelible spirit, in order to deeply commemorate the revolutionary martyrs and carry forward the great spirit of the Resistance War, the Party Branch Committee of the Communist Party of China at Shenzhen Efung Investment Management Enterprise (Limited Partnership) organized a viewing of the military parade.Through this event, members observed the remarkab...
浏览次数:1
发布时间: 2025 - 08 - 29
Today, on the Qixi Festival, the starry river is bright, and magpies form a bridge for lovers' meeting, symbolizing beautiful connections and journeys. In the vast sea of hard tech investment, the "mutual journey" between Ef Capital and its portfolio companies has also borne fruit.Looking back at August, several biopharmaceutical companies invested by Ef Capital performed outstandingly, achieving a series of breakthroughs in financing progress, clinical updates, and regulatory approvals.Notably, two portfolio companies, 3D Medicines and Kaitao Biotech, "joined hands" in...
浏览次数:1
85页次17/22首页PREV...  12131415161718192021...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务